News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
The Pune centre expands its presence beyond Bangalore and Hyderabad
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
The company reports revenue growth of 26% and PAT growth of 21% YoY
Subscribe To Our Newsletter & Stay Updated
